B cell receptor induced IL-10 production from neonatal mouse CD19+CD43- cells depends on STAT5 mediated IL-6 secretion

  1. Jiro Sakai
  2. Jiyeon Yang
  3. Chao-Kai Chou
  4. Wells W Wu
  5. Mustafa Akkoyunlu  Is a corresponding author
  1. United States Food and Drug Administration, United States

Abstract

Newborns are unable to reach the adult-level humoral immune response partly due to the potent immunoregulatory role of IL-10. Increased IL-10 production by neonatal B cells has been attributed to the larger population of IL-10-producting CD43+ B-1 cells in neonates. Here, we show that neonatal mouse CD43- non-B-1 cells also produce substantial amounts of IL-10 following B cell antigen receptor (BCR) activation. In neonatal mouse CD43- non-B-1 cells, BCR engagement activated STAT5 under the control of phosphorylated forms of signaling molecules Syk, Btk, PKC, FAK and Rac1. Neonatal STAT5 activation led to IL-6 production, which in turn was responsible for IL-10 production in an autocrine/paracrine fashion through the activation of STAT3. In addition to the increased IL-6 production in response to BCR stimulation, elevated expression of IL-6Rα expression in neonatal B cells rendered them highly susceptible to IL-6 mediated STAT3 phosphorylation and IL-10 production. Finally, IL-10 secreted from neonatal mouse CD43- non-B-1 cells was sufficient to inhibit TNF-α secretion by macrophages. Our results unveil a distinct mechanism of IL-6-dependent IL-10 production in BCR-stimulated neonatal CD19+CD43- B cells.

Data availability

Sequencing data have been deposited in GEO under accession code GSE200955

The following data sets were generated

Article and author information

Author details

  1. Jiro Sakai

    Laboratory of Bacterial Polysaccharides, United States Food and Drug Administration, Silver Spring, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Jiyeon Yang

    Laboratory of Bacterial Polysaccharides, United States Food and Drug Administration, Silver Spring, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Chao-Kai Chou

    Facility for Biotechnology Resources, United States Food and Drug Administration, Silver Spring, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Wells W Wu

    Facility for Biotechnology Resources, United States Food and Drug Administration, Silver Spring, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Mustafa Akkoyunlu

    Laboratory of Bacterial Polysaccharides, United States Food and Drug Administration, Silver Spring, United States
    For correspondence
    Mustafa.Akkoyunlu@fda.hhs.gov
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9958-4031

Funding

No external funding was received for this work.

Ethics

Animal experimentation: The mouse experiments described in this study were performed in accordance with the US Food and Drug Administration/Center for Biologics Evaluation and Research Institutional Animal Care and Use Committee guidelines (permit 2002-31 and 2017-45).

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,722
    views
  • 165
    downloads
  • 2
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jiro Sakai
  2. Jiyeon Yang
  3. Chao-Kai Chou
  4. Wells W Wu
  5. Mustafa Akkoyunlu
(2023)
B cell receptor induced IL-10 production from neonatal mouse CD19+CD43- cells depends on STAT5 mediated IL-6 secretion
eLife 12:e83561.
https://doi.org/10.7554/eLife.83561

Share this article

https://doi.org/10.7554/eLife.83561

Further reading

    1. Immunology and Inflammation
    Josep Garnica, Patricia Sole ... Pere Santamaria
    Research Article

    Chronic antigenic stimulation can trigger the formation of interleukin 10 (IL-10)-producing T-regulatory type 1 (TR1) cells in vivo. We have recently shown that murine T-follicular helper (TFH) cells are precursors of TR1 cells and that the TFH-to-TR1 cell transdifferentiation process is characterized by the progressive loss and acquisition of opposing transcription factor gene expression programs that evolve through at least one transitional cell stage. Here, we use a broad range of bulk and single-cell transcriptional and epigenetic tools to investigate the epigenetic underpinnings of this process. At the single-cell level, the TFH-to-TR1 cell transition is accompanied by both, downregulation of TFH cell-specific gene expression due to loss of chromatin accessibility, and upregulation of TR1 cell-specific genes linked to chromatin regions that remain accessible throughout the transdifferentiation process, with minimal generation of new open chromatin regions. By interrogating the epigenetic status of accessible TR1 genes on purified TFH and conventional T-cells, we find that most of these genes, including Il10, are already poised for expression at the TFH cell stage. Whereas these genes are closed and hypermethylated in Tconv cells, they are accessible, hypomethylated, and enriched for H3K27ac-marked and hypomethylated active enhancers in TFH cells. These enhancers are enriched for binding sites for the TFH and TR1-associated transcription factors TOX-2, IRF4, and c-MAF. Together, these data suggest that the TR1 gene expression program is genetically imprinted at the TFH cell stage.

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Stephanie Guillet, Tomi Lazarov ... Frédéric Geissmann
    Research Article

    Systemic lupus erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in vivo in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, NRTKs regulate activation, migration, and proliferation of immune cells. We found that the patients’ ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced pluripotent stem cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages.